Noema Pharma AG today announced the presentation of Phase 2a study results evaluating cendifensine in menopausal women ...
Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate ...
Researchers at Skoltech have developed an ultra-compact electro-optic modulator based on silicon photonics and plasmonics ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
After two years of treatment, there was an 87% reduction in death in treated patients compared with those who received ...
The Food and Drug Administration (FDA) has placed a hold on the enrollment of new patients in the phase 3 ENIGMA-TRS 2 study evaluating evenamide in treatment-resistant schizophre ...
The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...
The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.
Addex spin-out company Neurosterix on track to complete phase 1 study of NTX-253 for schizophrenia in Q2 2026: Geneva, Switzerland Saturday, April 25, 2026, 14:00 Hrs [IST] Addex ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...
Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results